| answer text |
<p>NHS Blood and Transplant has a selection and allocation policy for each organ,
ensuring a transparent process to balance reducing mortality on waiting lists and
matching donor lungs with recipients to provide the best outcome for all listed patients.
The algorithm is not dependent on the primary disease and patients are only placed
on the transplant list after maximal therapy.</p><p>NHS Blood and Transplant’s Lung
Advisory Group would regard a trial of Trikafta (Kaftrio) as an important pre-referral
step and most cystic fibrosis physicians would prescribe this prior to the referral
of patients for transplantation.</p>
|
 |
